SCHEMBL17327550

SCHEMBL17327550

CS(=O)(=O)NNC(=O)c1cc(-c2ccc(Br)cc2)nc2ccncc12

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.53
▸ KMT2A Q03164 5/20 0.53
▸ MAPT P10636 5/20 0.47
▸ ALDH1A1 P00352 4/20 0.47
▸ LMNA P02545 3/20 0.47
▸ GAA P10253 2/20 0.47
▸ P4HB P07237 1/20 0.47
▸ EPRS1 P07814 1/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ CYP2C9 P11712 2/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ GLA P06280 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15919365 0.84 KMT2A (0.56) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL15904896 0.84 MEN1 (0.42) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL15905078 0.81 MEN1 (0.51) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL15919433 0.81 KMT2A (0.56) MEN1KMT2AMAPTEPRS1CYP2C9
SCHEMBL15905102 0.80 EPRS1 (0.64) MEN1KMT2AALDH1A1GAAEPRS1
SCHEMBL15905538 0.80 PLA2G2A (0.56) MEN1KMT2AALDH1A1EPRS1KDM4E
SCHEMBL15919411 0.78 KMT2A (0.53) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL15905110 0.76 MAPK10 (0.50) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL15904915 0.75 MAPT (0.48) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL15919281 0.75 ACACB (0.41) MEN1KMT2AMAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 — — US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO MEN1 511/4885KMT2A 1886/4885MAPT 2507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback